OUR MISSION:

amfAR, The Foundation for AIDS Research, is dedicated to ending the global AIDS epidemic through innovative research.
<table>
<thead>
<tr>
<th>CONTENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Progress in the Face of a New Pandemic</td>
</tr>
<tr>
<td>Research</td>
</tr>
<tr>
<td>Public Policy</td>
</tr>
<tr>
<td>TREAT Asia</td>
</tr>
<tr>
<td>Public Information</td>
</tr>
<tr>
<td>Grants, Fellowships, and Awards</td>
</tr>
<tr>
<td>Research Grants, Fellowships, and Awards</td>
</tr>
<tr>
<td>TREAT Asia Grants and Awards</td>
</tr>
<tr>
<td>Financial Highlights</td>
</tr>
<tr>
<td>Leadership and Advisory Committees</td>
</tr>
<tr>
<td>Board of Trustees</td>
</tr>
<tr>
<td>Scientific Advisory Committee</td>
</tr>
<tr>
<td>Program Advisory Council</td>
</tr>
<tr>
<td>Management Group</td>
</tr>
</tbody>
</table>
PROGRESS IN THE FACE OF A NEW PANDEMIC

SARS-CoV-2, the virus that causes COVID-19

RESEARCH

amfAR Fund to Fight COVID-19

Temporarily expanding its efforts to include research on the novel coronavirus, in April 2020 amfAR established the amfAR Fund to Fight COVID-19, announcing its first COVID grants in July.

- A common and often deadly consequence of advanced COVID-19 disease is acute kidney injury. Cells in the kidney express the ACE2 protein, which serves as a receptor for the virus and may underlie the kidney damage. Dr. Matthias Kretzler of the University of Michigan, Ann Arbor, was awarded $155,650 to use a clever technique to understand what happens in the kidney of those with COVID-19. By comparing patients receiving anti-inflammatory treatment to those who were not, Dr. Kretzler aimed to develop a tool to predict who would most benefit from this kind of treatment.

- A second grant of $192,000 was awarded to Dr. Daniel Kaufmann of the University of Montreal for a study of antibody responses to COVID-19. Dr. Kaufmann was able to tap into the Quebec COVID-19 Biobank, established at the beginning of the pandemic to collect biological samples from patients admitted to the hospital. These banked samples, collected from the time of admission through several months of follow-up, allowed Dr. Kaufmann and his team to study why some people develop antibodies and others do not, how we can predict whether those antibodies protect against reinfection, and how long the protection lasts.

Countdown to a Cure for AIDS

To accelerate the search for a cure, in 2015 amfAR launched its Countdown to a Cure for AIDS initiative. To date, 87 grants totaling more than $50 million have been awarded through the Countdown, supporting research conducted by 300 scientists working at more than 100 institutions in 16 countries. Structured to provide sustained support for a range of studies that advance both emerging and established ideas, the Countdown comprises the following components:

- The amfAR Institute for HIV Cure Research was established in 2015 with a $20 million grant over five years to the University of California, San Francisco (UCSF). Researchers at the Institute have been laying the groundwork for a complex clinical study employing a three-pronged approach to eradicating HIV. A therapeutic vaccine is combined with an immune adjuvant—a drug often used to boost the efficacy of vaccines—that has been shown in clinical trials to have additional anti-HIV effects. The third component combines two broadly neutralizing antibodies,
the source of much optimism in the cure field for their ability not only to kill viruses that are produced by infected cells, but also to direct the immune system to kill the very cells producing those viruses. In August 2020, the trial got underway when the first injection was given to the first participant.

**ARCHE, the amfAR Research Consortium on HIV Eradication,** supports collaborative teams of scientists in the U.S. and around the world working on a range of HIV cure strategies. For several years, amfAR’s ARCHE-GT consortium has been designing and fine-tuning three gene therapy approaches to curing HIV that could be delivered in vivo—directly to the patient.

One approach involves the generation of chimeric antigen receptor (CAR) stem cells that are designed specifically to kill virus-infected cells. A second is to spur liver cells to produce HIV-specific antibodies. The third is to deliver an enzyme that would edit the virus out of infected cells. Each of these three tools is now ready to be tested in combination.

In February 2020, Dr. Hildegard Büning of Hannover Medical School, Germany, was awarded $1.65 million for a preclinical study to test their effectiveness. This complex gene therapy study will provide vital signposts informing further curative gene therapy studies.

**Uniting data scientists with HIV researchers,** one-year Magnet Grants of up to $150,000 are harnessing advances in machine learning algorithms to find patterns in the vast trove of data researchers have amassed over the past decade. Already a critical component of the success of precision medicine, machine learning is able to identify patterns in health and disease that we wouldn’t know to look for. In February 2020, amfAR awarded grants totaling about $600,000 to research teams in the U.S., Australia, and Brazil.

The HIV reservoir may expand when infected T cells grow in number to fight invading pathogens. Identifying how to limit expansion in reservoir cells while maintaining normal expansion in uninfected T cells would be an important step toward a cure. Magnet grantees Dr. Ya-Chi Ho has collected vast amounts of data on the activity of over 133,000 T cells, including rare reservoir cells, across seven people living with HIV. With the help of bioinformatician Dr. David van Dijk, the team is building machine-learning tools to identify mediators of T cell expansion that affect reservoir cells specifically.

Collaborating with data scientists Drs. Doron Betel and Friederike Dundar, Dr. Brad Jones aims to identify, using public and private datasets, differences between reservoir cells that survived attack by the immune system and those that were susceptible. Then the researchers will analyze cancer datasets to determine whether those protective factors identified in HIV are also present in cancer—a disease that may have FDA-approved drugs to target those factors.

By understanding exactly where HIV inserts itself in our genome, researchers can make inferences about how location may predict latency. Dr. Sharon Lewin, a world-renowned HIV cure researcher, has teamed up with Dr. Daniel Cameron, a former software developer turned academic bioinformatician, to develop a data science mapping pipeline to chart the hard-to-reach areas of our genome. Using over 600GB of cloud computing memory and mining 30 public and private datasets, the researchers aim to gain a more complete understanding of what insertion site means for HIV latency—and ultimately cure.

**Synergy Grants** capitalize on unforeseen possibilities for collaboration and enable us to add new study arms onto existing amfAR grants. In February 2020, amfAR awarded $50,000 to Dr. Jonathan Li of The Brigham and Women’s Hospital in Boston. In 2019, amfAR launched Project PTC, the largest study to date aimed at discovering the underpinnings of post-treatment control—viral control in the absence of antiretroviral therapy (ART). Led by Dr. Li, one of the world’s leading PTC researchers, the team has been using cutting-edge tools to explore immune control and viral dynamics. The new grant recruited Dr. Michael Seaman, an expert in HIV antibody responses at Harvard Medical School. This additional expertise could help determine whether antibodies help shape the ability of PTCs to control virus once they stop taking ART. Discovering what leads to post-treatment control in these rare individuals could help in designing methods to achieve durable ART-free control in all people living with HIV.

**Mathilde Krim Fellowships in Basic Biomedical Research**

These fellowships support bright young scientists advancing innovative solutions to HIV/AIDS. In December 2019, amfAR announced two new Krim Fellows: Dr. Maolin Lu of Yale University in New Haven, CT, and Dr. Shaheed Abdulhaq, of Oregon Health and Science University in Portland, OR. Each fellow is awarded approximately $150,000 over two years.

**COVID-19 Pause**

Due to the COVID-19 pandemic, in March 2020 amfAR temporarily paused its ongoing HIV research grants with the exception of one
grant funded by the FAIR Foundation. The pause ended on July 1, 2020, for a clinical trial at the amfAR Institute for HIV Cure Research in San Francisco, and October 1 for other paused research.

Published Research

Research studies make the greatest impact on the HIV field and on the broader scientific community when they are published in scientific journals. In FY2020, 80 scientific publications resulted from amfAR-funded research. Examples include:

▶ Seeing Is Believing: Nuclear Imaging of HIV Persistence

*In Frontiers in Immunology*, Dr. Timothy Henrich of the amfAR Institute for HIV Cure Research and colleagues outlined a cutting-edge technique using the only EXPLORER PET scanner currently operational in the U.S. to visualize the places where HIV resides in host tissue cells. The machine is able to produce images that are approximately 40 times more sensitive than current technology in a fraction of the time. The technology may help researchers identify which tissues are responsible for HIV resurgence following treatment interruption as part of a cure intervention.

▶ Attacking Latent HIV with Convertible CAR T Cells, a Highly Adaptable Killing Platform

In the prestigious journal *Cell*, members of the amfAR Institute for HIV Cure Research reported the development of a new type of CAR T cell—one that can keep up with HIV’s ever mutating envelope. Convertible CAR T cells can target multiple strains of HIV without the need to manufacture as many different CAR T cells as there are strains. Harnessing the ability of this new platform to selectively kill HIV-infected cells, researchers may be able to develop more effective cure strategies in which latency-reversing agents reactivate latent HIV.

HIV Cure Summit

In November 2019, amfAR held its sixth annual HIV Cure Summit at the University of California, San Francisco (UCSF), where the amfAR Institute for HIV Cure Research is based. Leading amfAR-funded cure researchers detailed their progress and discussed the scientific challenges that continue to stand in the way of a cure. Dr. Rachel Rutishauser, for example, outlined the pioneering clinical trial at the Institute that will test a combination approach to curing HIV (see page 1).

Dr. Rowena Johnston, amfAR Vice President and Director of Research, discussed “societies of research,” displaying a visualization tool to show how in recent years HIV researchers are collaborating more than ever before. Speaking with Dr. Johnston, Loreen Willenberg, the “San Francisco patient,” shared her inspiring personal story, from her HIV diagnosis in 1992 to recognition by her doctors that she was somehow able to maintain undetectable viral levels without ever taking ART, to being an invaluable participant in HIV studies for over a decade.

Discussing post-treatment control of HIV, Drs. Peter Hunt of UCSF and Marcella Flores of amfAR outlined efforts to study the rare individuals—post-treatment controllers—who are able to naturally control their virus after stopping ART. A better understanding of how these individuals are able to do so could help researchers induce post-treatment control in other people living with HIV.

The Summit also featured a range of perspectives from members of the community advisory board for the amfAR Institute and other community leaders.
COVID-19. The study generated significant national media attention. Published in *Annals of Epidemiology* in July 2020, it has been cited in more than 100 publications including the *New England Journal of Medicine* and *JAMA*.

Also in July, a study by a multi-institutional team led by researchers at The George Washington University found that factors linked to structural racism put Latino communities nationwide at high risk of COVID-19. amfAR’s Greg Millett was senior author on the study. The researchers detailed contributing factors including crowded housing, air pollution and jobs in the meatpacking and poultry industry. The first national analysis of COVID deaths and cases among this group, it confirmed previous reports that Latinos were particularly hard hit by the virus.

In August, an amfAR study showed that disproportionately white counties in the U.S. had consistently lower rates of COVID-19 and HIV. Residential segregation, structural racism, and social determinants of health were noted as key factors driving diagnoses in nonwhite communities. With schools reopening in some states, the amfAR study suggested that comparatively higher COVID-19 diagnoses in non-white counties placed youth and adults in those counties at greater risk for infection.

As a companion resource for these studies on disparities, amfAR launched a new data dashboard tracking COVID-19 cases and diagnoses in U.S. counties with a large proportion of racial/ethnic minorities.

### Context Matters: Ending the HIV Epidemic Among Latinx

The federal government’s *Ending the HIV Epidemic* (EHE) plan has the goal of reducing new HIV infections by 90% in the next 10 years. This goal will not be met without eliminating disparities in access to services in the Latinx community. The current administration’s anti-immigrant rhetoric and policies make this unlikely to happen. Non-citizens and undocumented individuals will be less likely to seek testing, prevention, or treatment services if they fear deportation and arrest, or lose the opportunity to pursue legal status. And their families and communities may also be less likely to access services in order to protect themselves and undocumented people in their community.

Several administration actions directly undermined any efforts in the EHE plan to improve access to services among the Latinx community.

**What’s Helping?**

- **Ending the HIV Epidemic (EHE) plan**
  - 90% targeted decrease in HIV infections by 2030
  - 48 states, plus Washington, DC, and San Juan, PR.
  - 7 counties targeted under EHE plan

**What’s Not?**

- **Demonization of immigrants and Latinx**
  - Leads to increased stigma, real and feared, preventing groups from accessing services
- **Fear of arrest and deportation**
  - Prevents Latinx, especially the undocumented and their families, from accessing services
- **Public charge rule**
  - Drives noncitizens to avoid using public benefits including health services
- **Federal immigration restrictions**
  - Restricts access for immigrants who do not have health insurance from entering legally

One of a series of infographics illustrating priority issues for amfAR’s Public Policy Office.
Also in August, amfAR published an issue brief on gender-based violence (GBV) in South Africa during the coronavirus pandemic. The analysis found significant barriers to service availability and called for government action and resources to be directed to ensure reliable access to GBV services for the duration of COVID-19 and beyond.

amfAR also published several op-eds early in the pandemic. In February 2020, amfAR Senior Policy and Medical Advisor Dr. Susan Blumenthal penned an op-ed for The Hill outlining five ways to prepare for the coronavirus. In March she wrote for The Advocate on the essential lessons from the AIDS epidemic that could be applied to the COVID-19 crisis, followed by two op-eds in April: one in Thrive Global argued that young people held the key to “flattening the curve,” and the other, for CNN, made the case for studying the effects of COVID on women.

HIV and the Opioid Epidemic

amfAR’s Opioid & Health Indicators Database (opioid.amfar.org) is a free web platform designed to support lawmakers, communities, and advocates in making informed decisions about the opioid epidemic and its impact on HIV and hepatitis C. It provides local to national statistics using reliable data sources on new HIV and hepatitis C infections, opioid use and overdose death rates, and the availability of services like drug treatment programs and syringe exchange services.

Advocating on the Global Stage

In November 2019, amfAR published an issue brief outlining the impacts of the “global gag rule” for the Global Fund to Fight AIDS, Tuberculosis and Malaria. Reinstated and expanded by President Trump in 2017 [and subsequently rescinded by the Biden administration], the policy restricted non-U.S.-based or foreign NGOs from receiving American financial aid if they perform, counsel on, or refer for abortion, or advocate for its liberalization outside of limited exceptions. The issue brief concluded that the policy was linked to “disruptions in HIV programming—including basic HIV prevention services such as condom distribution, HIV testing, and voluntary medical male circumcision programming to prevent HIV.”

amfAR maintains the PEPFAR Monitoring, Evaluation, and Reporting database (mer.amfar.org). Launched in 2018, the database enables policymakers, public health officials, advocates, and other stakeholders to access a wide range of programmatic data on PEPFAR (the U.S. President’s Emergency Plan for AIDS Relief) and includes downloadable PDFs, maps, data visualizations, and district-level data. The database complements amfAR’s PEPFAR database (copsdata.amfar.org), which highlights planned funding by program area, country and organization for each year that has been publicly released.

In October 2019, amfAR published a 20-page report titled Data Watch: Data Accessibility from Global Funders of HIV, TB and Malaria Programming. The report assessed the adequacy of information regarding who is being funded in a given community, what they have been funded to do, and whether they have delivered as contracted.

AIDS 2020

amfAR’s Public Policy Office participated in the biennial International AIDS Conference—the premier global meeting for the HIV field—July 6-10. Delegates came together virtually to hear about and discuss the latest HIV research findings and policy issues, and intersections with the coronavirus.

Public Policy Director Greg Millett delivered an opening plenary talk that contextualized 40 years of disparities throughout the HIV pandemic, and joined a live Q&A session with Dr. Linda-Gail Bekker of the Desmond Tutu HIV Centre at the University of Cape Town, former president of the International AIDS Society.

amfAR’s Deputy Director of Public Policy Brian Honermann presented at a virtual community workshop that focused on the effective use of data tools to drive impactful change in the HIV response. And Policy Associate Jennifer Sherwood gave a symposium talk on whether current approaches to collecting data capture the full impact of HIV on women.

The conference featured many talks on the intersection of HIV and COVID-19. Greg Millett joined Merck Vice President of Social Innovation Carmen Villar for a “fireside chat” to discuss a paper Millett co-authored assessing the differential impacts of COVID-19 on black communities. Millett also joined Chris Collins of Friends of the Global Fight and others in a session titled How did they do it? What successful communities can teach all of us about making dramatic progress against HIV epidemics and what this means in the age of COVID. The session was a one-year follow-up to a report co-authored by amfAR, AVAC and Friends of the Global Fight titled Translating Progress into Success to End the AIDS Epidemic.

amfAR VP and Director of Public Policy Greg Millett delivered an opening plenary address at AIDS 2020, the virtual International AIDS Conference.
amfAR’s TREAT Asia (Therapeutics Research, Education, and AIDS Training in Asia) program is a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of treatments for HIV and its co-infections to adults and children across the Asia-Pacific through research, education, and advocacy. The TREAT Asia Network encompasses 21 adult and 20 pediatric sites throughout the region, which collaborate on a variety of projects. TREAT Asia scientists produced 33 publications in peer-reviewed medical journals in 2020.

Gathering Critical Information

TREAT Asia pioneered the region’s first adult observational database for HIV/AIDS, which now includes anonymous data from nearly 10,000 patients at 21 clinical sites in 12 countries. The TREAT Asia HIV Observational Database (TAHOD) gathers information to inform the development of more effective research and treatment programs and helps define treatment standards specific to HIV/AIDS in Asia. The TAHOD-LITE database, an extension of TAHOD, contains data from over 37,000 HIV-positive patients across ten TREAT Asia network sites and aims to increase the scope of adult data collection by gathering a subset of core variables from all HIV-infected patients who have sought care at selected TAHOD sites.

A Global Collaboration

In partnership with the Kirby Institute at the University of New South Wales, TREAT Asia manages the Asia-Pacific section of the International epidemiology Databases to Evaluate AIDS (IeDEA), a global collaboration established by the U.S. National Institute of Allergy and Infectious Diseases.

Improving Care for Children

The TREAT Asia Pediatric HIV Observational Database is a regional pediatric HIV study set up by TREAT Asia in 2006. It was modeled on the adult database and includes data from more than 7,400 children and adolescents at 17 clinical sites in Cambodia, India, Indonesia, Malaysia, Thailand, and Vietnam.

Integrating HIV, Mental Health, and Implementation Science Research

In 2019, the U.S. National Institutes of Health awarded a five-year, $1.4 million grant to TREAT Asia and Columbia University to establish an innovative platform for integrating HIV, mental health, and implementation science research in the Asia-Pacific region. The objective of the CHIMERA program (Capacity development for HIV and mental health research in Asia) is to address the dual and interlinked burdens of HIV and mental health. Co-led by Principal Investigators Dr. Annette Sohn, amfAR vice president and director of TREAT Asia, and Dr. Milton Wainberg, professor of clinical psychiatry at Columbia University and the New York State Psychiatric Institute, the program aims to build a team within the Asia-Pacific with the capacity to lead regional HIV-mental health-implementation science research that will inform public health policy and improve the quality of clinical care for people living with HIV.

The program is nested within the IeDEA (see above) Asia-Pacific regional research network that TREAT Asia directs. CHIMERA creates the opportunity to bring together stellar training faculty from academic centers and public health and development agencies within the region and across the world, and builds on existing NIH-funded mental health research being conducted through IeDEA Asia-Pacific.

In February 2020, a workshop for CHIMERA fellows was held in Bangkok, covering implementation science frameworks and study designs, informatics for research and public health, and the responsible conduct of research. Fellows also met with TREAT Asia and faculty to discuss their pilot research proposals.

The COVID-19 Pandemic

In April 2020, TREAT Asia led the submission of a letter to the Regional Directors of World Health Organization (WHO) South-East
Asia and Western-Pacific. Signed by 32 regional and national civil society organizations, the letter called for WHO to play a greater role in ensuring continuity of HIV-related healthcare services during the COVID-19 public health emergency in the Asia-Pacific.

TREAT Asia is collaborating with the Institute of HIV Research and Innovation (IHRI), Thai Red Cross AIDS Research Center (TRC-ARC) laboratory, and the NIH Vaccine Research Center to conduct SARS-CoV-2 serologic assays of Thai adults taking and not taking antiretroviral drugs for pre-exposure prophylaxis and treatment of HIV. In September 2020, more than 1,800 samples were sent to the National Institutes of Health.

Throughout the year, TREAT Asia participated in various meetings held virtually with organizations and community members from countries throughout the Asia-Pacific region to navigate the impacts of COVID-19 on critical HIV and hepatitis services and initiatives.

Helping Adolescents Transition to Adult Care

More than one in four new HIV infections in the Asia-Pacific occur in young people aged 15–24 years. Continuing its commitment to helping adolescents transition to adult care, in 2019 TREAT Asia initiated plans for a study of adolescents and young adults living with HIV. A total of 75 HIV-disclosed adolescents with HIV were enrolled from three participating sites in Thailand and the Philippines for initial and 12-month follow-up assessments. Critical outcomes including viral suppression, treatment adherence, pregnancy, and mortality will be assessed.

AIDS 2020

Asia had a strong presence at the 23rd International AIDS Society Conference (AIDS 2020) held virtually in July. TREAT Asia Director Dr. Annette Sohn moderated a prime session Q&A on pediatric HIV along with Martina Penazzato of the World Health Organization. Dr. Sohn also spoke at a workshop addressing the essential skill for early-career HIV researchers of writing and successfully submitting scientific papers to peer-reviewed journals. Numerous TREAT Asia partner investigators and affiliates also gave poster presentations at the conference.

TREAT Asia also participated in the fifth Asia Pacific AIDS & Co-Infections Conference (APACC), held virtually in October 2020. APACC is a regional-level HIV research conference that provides opportunities for local clinicians, students, and researchers to submit abstracts for presentation.

The 2019 TREAT Asia Annual Network Meeting was held in October 2019 in Bangkok, Thailand, where adult and pediatric investigators, donors, and program partners gathered to review progress on the network’s research agenda, hear about regional HIV-related policy priorities, and plan for future initiatives.

THE GMT INITIATIVE

The two implementation science studies being supported by amfAR’s GMT Initiative came to an end in 2019, bringing the initiative to a close. The three-year projects, in Myanmar and Thailand, were aimed at determining the most effective ways of engaging gay men, other men who have sex with men (MSM), and transgender individuals (collectively, GMT) at risk of infection or already living with HIV. The goal was to help those who were HIV-negative stay uninfected, and help HIV-positive individuals to begin and remain on treatment. A third project, in Peru, ended in 2018.

PUBLIC INFORMATION

amfAR disseminates information on important HIV-related research, treatment, prevention, and policy issues for diverse audiences to increase awareness and knowledge of the pandemic. amfAR publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policymakers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for HIV.

The COVID-19 Pandemic

When the COVID-19 crisis emerged in early 2020, amfAR dedicated a section of its website to information on the coronavirus and the intersection of HIV and COVID-19 in particular. The section featured resources for people living with HIV and news of the latest studies as more and more data emerged. Audiovisual content included a video announcement of the launch of the amfAR Fund to Fight COVID-19 and a series of interviews featuring amfAR VP and Director of Research Dr. Rowena Johnston and amfAR grantees who had quickly pivoted to research on COVID-19. These informative interviews covered topics such as testing, vaccine development, experimental treatments, and COVID in children, and garnered tens of thousands of views.

Educational Materials

amfAR’s newsletter Innovations is published twice a year and distributed to more than 40,000 people, while a monthly email newsletter reaches approximately 10,000 readers.
The Foundation’s websites—www.amfar.org and www. curecountdown.org—feature news, interviews, and original articles covering HIV research, policy, the global epidemic, and amfAR programs and activities. The websites attract a combined average of 46,000 visitors per month. amfAR also creates and distributes reports, press releases, and updates on major HIV/AIDS issues and conducts public service advertising campaigns that have been instrumental in educating policymakers, healthcare professionals, people living with HIV/AIDS, and the public.

amfAR’s Public Information team also works closely with the Public Policy Office (see above) to produce a wide range of issue briefs, facts sheets, infographics, and reports.

Epic Voices

amfAR’s Epic Voices, an online video series that aims to reenergize the response to HIV among millennial and LGBTQ communities, continued to generate significant engagement in 2020. A ten-episode Instagram IGTV series featuring the videos received more than 7,500 views. The series profiles HIV activists across the country who share their unique journeys, their insights on living with HIV, and the bold steps they have taken in the fight against the epidemic.

Social Media

amfAR has vigorously expanded its presence in the social media arena, reaching large numbers of people, including a younger demographic that is often less educated about HIV and the AIDS epidemic. The Foundation regularly adds educational and fundraising news and information to its Facebook page and Twitter and Instagram feeds. amfAR has over 76,000 likes on Facebook, more than 43,000 Twitter followers, and 159,000 Instagram followers.

Media Outreach


Celebrity Support

amfAR’s public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the Foundation’s mission. Support of amfAR by prominent public figures began with the late Dame Elizabeth Taylor, amfAR’s Founding International Chairman, and others have followed in her footsteps.

amfAR is profoundly grateful for the continuing support of celebrities from all over the world, including Iman, James Corden, Tom Ford, Cheyenne Jackson, Paris Jackson, Heidi Klum, Katy Perry, Julia Roberts, Alan Cumming, Christina Aguilera, Gwyneth Paltrow, Lily Aldridge, Adrien Brody, Andy Cohen, Diplo, Padma Lakshmi, Billy Porter, Zac Posen, Laid Ribeiro, Coco Rocha, Carine Roitfeld, Amber Valletta, Virgil Abloh, Alessandra Ambrosio, Peter Dundas, Ashley Graham, Winnie Harlow, Miranda Kerr, Karlie Kloss, Karolina Kurkova, Adriana Lima, Jasmine Sanders, Shanina Shaik, Irina Shayk, Joan Smalls, Lara Stone, Jasmine Tookes, and Diane von Fürstenberg.

amfAR honored legendary model and entrepreneur Iman at the 2020 New York Gala for her contributions to the fight against AIDS.
### 2020 RESEARCH GRANTS, FELLOWSHIPS

All projects below were awarded funding during the period October 1, 2019 through September 30, 2020.

1Supported with funds provided by the FAIR Foundation

#### amfAR FUND TO FIGHT COVID-19

**Predictors of SARS-CoV-2 antibody responses after severe COVID**

Daniel Kaufmann, MD  
Université de Montréal, Centre de Recherche du CHUM  
Montreal, Canada  
$209,712

**Protecting epithelial cell organ from COVID-19 attack**

Matthias Kretzler, MD, PhD  
The University of Michigan  
Ann Arbor, MI  
$155,650

#### amfAR RESEARCH CONSORTIUM ON HIV ERADICATION (ARCHE): GENE THERAPY

**Preclinical in vivo non-human primate study of combined treatment strategies**

Hildegard Büning, PhD  
Hannover Medical School  
Hannover, Germany  
$1,558,021

#### IMPACT GRANTS: GAINING INSIGHTS FROM THE CLINIC

**Identification of integrative multi-omics signature predictive of HIV replication control without the use of ART**

Simone Gonçalves da Fonseca, PhD  
Fundação de Apoio à Pesquisa (FUNAPE)  
Goiânia, Brazil  
$63,040

**Deep learning methods to personalize antibody therapeutics for delaying viral rebound after cessation of ART**

Hillel Haim, MD, PhD  
University of Iowa  
Iowa City, IA  
$149,995

**The driving force of the clonally expanding HIV-1-infected cells - a single-cell approach**

Ya-Chi Ho, MD, PhD  
Yale University  
New Haven, CT  
$150,000

**Integrating Transcriptomic and Proviral Integration Site Data-Sets to Define Mechanisms of ‘CTL Resistance’ in Reservoir**

Brad Jones, PhD  
Well Medical College of Cornell University  
New York, NY  
$150,000

**A hidden reservoir? An in-depth analysis of HIV integration across the entire human genome**

Sharon Lewin, FRACP, PhD  
University of Melbourne  
Melbourne, Australia  
$149,999

#### SYNERGY GRANT: GAINING INSIGHTS FROM THE CLINIC

**Humoral Immune Response in HIV Rebound**

Jonathan Li, MD, MMSc  
The Brigham and Women’s Hospital, Inc.  
Boston, MA  
$50,000

#### MATHILDE KRIM FELLOWSHIPS IN BIOMEDICAL RESEARCH

**Harnessing Universal MHC-E-Restricted T cell Receptors for HIV Cure**

Shaheed Abdulhaqq, PhD  
Oregon Health and Science University  
Portland, OR  
$150,000

**HIV-1 fusion studied by parallel single molecule FRET and cryo-electron tomography**

Maolin Lu, PhD  
Yale University  
New Haven, CT  
$150,000
2020 TREAT ASIA
GRANTS AND AWARDS

All projects listed below were awarded funding for the period October 1, 2019, through September 30, 2020.

1Supported by National Institutes of Health federal award number U01AI069907, with funds from the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and Kidney Diseases, and the Fogarty International Center

2Supported by National Institutes of Health federal award number D43TW011302, funded by the Fogarty International Center and the National Institute of Mental Health

3Supported with funds provided by Life Ball.

AUSTRALIA

University of New South Wales
Sydney
Matthew G. Law, PhD
IeDEA Asia-Pacific Research Collaboration: Data Management and Analysis Center
$552,520

AUSTRALIAN HIV OBSERVATIONAL DATABASE (AHOD) SITES

O’Brien Street Practice
Adelaide
William Donohue, MBBS
$1,275

Sunshine Coast Hospital and Health Service
Birtinya
David Sowden, MBBS
$7,500

Sexual Health and HIV Service In Metro North
Brisbane
Diane Rowling, MBBS, MTH, F(PhM), RACP, FACSHM
$7,500

Cairns Sexual Health Service
Cairns North
Darren Russell, MD
$7,500

RPA Sexual Health Clinic
Camperdown
David Templeton, PhD
$7,425

Melbourne Sexual Health Centre
Carlton
Richard Teague, MBBS (Monash Uni), FRACGP, FRACShM
$5,475

Monash Health - Clayton
Clayton
Ian Woolley, MBBS, FRACP
$7,500

D.A. Ellis Pty., Ltd.
Coffs Harbour
David Ellis, MBBS
$450

Northern Territory of Australia Dept of Health through Top End Health Service
Manoji Gunathilake, MBBS, MD, FACSHM
$2,100

Nepean Blue Mountains Local Health District, Blue Mountains Sexual Health and HIV Clinic
Katoomba
Eva Jackson, MBBS, FACSHM
$1,950

Nepean Blue Mountains Local Health District, Nepean Sexual Health Clinic
Kingswood
Eva Jackson, MBBS, FACSHM
$1,950

Sexual Health and AIDS Services (SHAIDS)
Lismore
David Smith, MBBS, DipVen, FACSHM, GradDip BA
$7,500

Victorian HIV Service, Infectious Diseases Department, The Alfred Hospital
Melbourne
Jennifer Hoy, MBBS
$7,500

Northside Clinic (Vic) Pty Ltd
North Fitzroy
Richard Moore, MBBS
$7,500

Prahran Market Clinic Pty Ltd
Prahran
Norman Roth, MBBS, FACSHM
$7,350

East Sydney Doctors
Sydney
David Baker, MB, ChB, Dip Med (Sexual Health), DCH
$7,500

Holdsworth House Medical Practice
Sydney
Mark Bloch, MD
$7,500

St. Vincent’s Hospital Sydney Limited
Sydney
Andrew Carr, MD
$7,500

Sydney Sexual Health Centre, Sydney Hospital
Sydney
Rick Varma, MBBS, MRCP
$6,300

Taylor Square Private Clinic
Sydney
Robert Finlayson, MBBS, (Syd) Di FACHSHM, DipVen, MB BS
$6,525

Clinic 468, HNE Sexual Health, Hunter New England Local Health District
Tamworth NEMSC
Nathan Ryder, MD
$1,650

Illawarra Shoalhaven Local Health District
Warrawong
Katherine Brown, MD
$1,725

CAMBODIA

National Center for HIV/AIDS, Dermatology & STDs / Cambodia National Institute of Public Health
Phnom Penh
Ly Penh Sun, MD, MSc
TAHOD Low Intensity Transfer (TAHOD-LITE)
$9,500

TREAT Asia HIV Observational Database (TAHOD)
$20,800

TREAT Asia Pediatric HIV Observational Database (TApHOD) Site
$25,000

CHINA

Queen Elizabeth Hospital
Hong Kong
Man Po Lee, MBBS
TAHOD Low Intensity Transfer (TAHOD LITE)
$7,500

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$22,800

INDIA

The Voluntary Health Services
Chennai
Naglingeswaran Kumarasamy, MD, MBBS, PhD
TAHOD Low Intensity Transfer (TAHOD-LITE)
$15,000 (funding awarded in 2020 for project years 14 & 15)

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$22,800

TREAT Asia Pediatric HIV Observational Database (TApHOD)
$7,500
BJ Medical College & Sassoon General Hospitals
Pune
Aarti Kinkar, MD, DCH, DNB, MRCP-Pediatrics UK
TREAT Asia Pediatric HIV Observational Database (TApHOD) $7,500¹

Shashikala Sangle, MD
IeDEA Sentinel Research Network (SRN)—Asia-Pacific
$113,765¹

TREAT Asia HIV Observational Database (TAHOD) including NCD Data $21,085¹

Treat Asia Pediatric HIV Observational Database (TApHOD) $7,500¹

Institute of Infectious Diseases
Pune
Sanjay Pujari, MD, MAHIVS, MBBS
TAHOD Low Intensity Transfer (TAHOD-LITE) $9,500

TREAT Asia HIV Observational Database (TAHOD) including NCD Data $22,300⁰

INDONESIA

Sanglah Hospital, Udayana University School of Medicine
Denpasar
Tuti Parwati Merati, MD, TAHOD Low Intensity Transfer (TAHOD-LITE) $8,000¹

TREAT Asia HIV Observational Database (TAHOD) including NCD Data $22,800⁰

Ketut Dewi Kumara Wati, MD
TAHOD Pediatric HIV Observational Database (TAPHOD) $7,500¹

Cipto Mangunkusumo General Hospital
Jakarta
Nila Kurniati, MD
TREAT Asia Pediatric HIV Observational Database (TAPHOD) $7,500¹

Evy Yunihastuti, MD, PhD
TAHOD Pediatric HIV Observational Database (TAPHOD) $7,500¹

PHILIPPINES

Asian Foundation for Tropical Medicine, Inc.
Muntinlupa City
Rossana Ditangco, MD
Substance use, Stigma, Depression and Disability among Adults with HIV in Asia (S2D2) $6,500

Research Institute for Tropical Medicine
Muntinlupa City
Rossana Ditangco, MD
Adolescent and Young Adult network of IeDEA (AYANI) Study Site $12,718¹

TREAT Asia HIV Observational Database (TAHOD) including NCD Data $22,300⁰

SOUTH KOREA

Yonsei University College of Medicine
Seoul
Jun Yong Choi, MD, PhD
TAHOD Low Intensity Transfer (TAHOD-LITE) $6,000¹

TREAT Asia HIV Observational Database (TAHOD) including NCD Data $17,640¹

TAIWAN

Taipei Veterans General Hospital
Taipei City
Yu-Jiun Chan, MD
TREAT Asia HIV Observational Database (TAHOD) $15,000¹

HIV-NAT / Thai Red Cross AIDS Research Centre
Bangkok
Anchalee Avihingsanon, MD, PhD
Substance use, Stigma, Depression and Disability among Adults with HIV in Asia (S2D2) $2,514¹

TREAT Asia HIV Observational Database (TAPHOD) $24,800¹

SINGAPORE

Tan Tock Seng Hospital
Singapore
Oon Tek Ng, MBBS, MRCP, MMed, MPH
TREAT Asia HIV Observational Database (TAHOD) $18,200⁰

MALAYSIA

Penang Hospital
Georgetown
Revathy Nallusamy, MBBS
TREAT Asia Pediatric HIV Observational Database (TAPHOD) $5,3763 (funding awarded in 2020 for project years 14 & 15)
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$22,800¹

Chiang Mai University - Research Institute for Health Sciences
Chiang Mai
Romaneer Chaiwarith, MD, MHS
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$23,800¹

Tavitiya Sudjaritruk, MD, ScM
Adolescent and Young Adult network of IeDEA (AYANI) Study Site
$17,182¹

Study on Pregnancy and Birth Outcomes among Youth living with HIV in Asia
$1,828¹

TREAT Asia Pediatric HIV Observational Database (TApHOD)
$15,000¹

Chiangrai Prachanukroh Hospital
Chiang Rai
Suwimon Khusuwan, MD
TAHOD Low Intensity Transfer (TAHOD-LITE)
$9,500¹

TREAT Asia Pediatric HIV Observational Database (TApHOD)
$7,500¹

Purple Haze Company Limited
Bangkok
Tarandeep Anand
The impact of online interventions on the HIV prevention/treatment cascade among MSM and TG individuals
$30,000¹

Little Birds Foundation
Bangkok
Usanee Janngeon
Quality of life development for adolescents and youth living with HIV
$10,000¹

USA
Johns Hopkins University
Baltimore, MD
Vidyave, MD, MPH & Amita Gupta, MDA study to evaluate the markers of lung impairment in HIV-TB coinfected Indian adults
$20,791¹

Epidemiology of HIV/AIDS and associated comorbidities in a public antiretroviral treatment (ART) clinic in Pune, India
$411,571¹ (funding awarded in 2020 for project years 14 & 15)

IeDEA Sentinel Research Network (SRN)—Asia-Pacific
$23,571¹

New Hope for Cambodian Children
Killeen, TX
John Tucker
HIV Education: New Hope for Cambodian Children
$20,024¹

Columbia University
New York, NY
Milton Wainberg, MD
Capacity development for HIV and mental health research in Asia (CHIMERA)
$46,250²

VIETNAM
Bach Mai Hospital
Hanoi
Do Duy Cuong, MD, PhD
TAHOD Low Intensity Transfer (TAHOD-LITE)
$8,000¹

National Hospital of Pediatrics
Hanoi
Nguyen Van Lam, MD, MSc
Study on Pregnancy and Birth Outcomes among Youth living with HIV in Asia
$1,230¹

National Hospital of Tropical Diseases
Hanoi
Pham Ngoc Thach, MD, PhD
TAHOD Low Intensity Transfer (TAHOD-LITE)
$8,000¹

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$22,300¹

Children’s Hospital 1
Ho Chi Minh City
Truong Huy Khanh, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD)
$20,000¹

Children’s Hospital 2
Ho Chi Minh City
Do Chau Viet, MD
Study on Pregnancy and Birth Outcomes among Youth living with HIV in Asia
$1,442¹

TREAT Asia Pediatric HIV Observational Database (TApHOD)
$20,000¹

¹Funding in US dollars
²Funding in local currency

579x24
FINANCIALS

EXPENSES

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program</td>
<td>$21,741,025</td>
</tr>
<tr>
<td>Fundraising</td>
<td>$4,533,696</td>
</tr>
<tr>
<td>Management and general</td>
<td>$2,357,534</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$28,632,255</strong></td>
</tr>
</tbody>
</table>

PROGRAM EXPENSES

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>$11,753,894</td>
</tr>
<tr>
<td>TREAT Asia</td>
<td>$4,546,418</td>
</tr>
<tr>
<td>GMT Initiative</td>
<td>0</td>
</tr>
<tr>
<td>Public Policy</td>
<td>$1,776,060</td>
</tr>
<tr>
<td>Public Information</td>
<td>$3,664,653</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$21,741,025</strong></td>
</tr>
</tbody>
</table>
### FINANCIAL HIGHLIGHTS
For the year ended September 30, 2020

#### Public Support and Revenue
- **Public support**: $2,700,163
- **Special events**: 5,760,796
- **Planned giving**: 3,066,238
- **Government funding**: 6,657,827
- **Investment income and other revenue**: 2,608,564

**Total public support and revenue**: $20,793,588

#### Expenses
- **Research**: $11,753,894
- **TREAT Asia**: 4,546,418
- **GMT Initiative**: 0
- **Public Policy**: 1,776,060
- **Public Information**: 3,664,653

**Total program services**: $21,741,025

- **Fundraising**: 4,533,696
- **Management and general**: 2,357,534

**Total supporting services**: $6,891,230

**Total expenses**: $28,632,255

#### Change in net assets
- **Net assets, beginning of year**: 49,484,561
- **(7,838,667)**

**Net assets, end of year**: $41,645,894

### STATEMENT OF FINANCIAL POSITION

#### Assets
- **Cash and investments**: $44,474,143
- **Pledges and receivables, net**: 4,479,604
- **Prepaid expenses and other assets**: 2,859,940
- **Furniture, equipment, and leasehold improvements, net**: 2,925,831

**Total Assets**: $54,739,518

#### Liabilities
- **Accounts payable and accrued expenses**: $2,489,524
- **CARES Act Paycheck Protection Program loan**: 1,643,364
- **Grants and fellowships payable, net**: 1,052,816
- **Deferred support and refundable advances**: 6,138,184
- **Other long-term liabilities**: 1,769,736

**Total liabilities**: $13,093,624

**Total net assets**: $41,645,894

**Total liabilities and net assets**: $54,739,518
Chairman of the Board*  
William H. Roedy  
Chairman, MTV International (retired)  
London United Kingdom  *(10/01/2019-06/26/2020)*

Vice Chair*  
Cindy Rachofsky  
Philanthropist  
Dallas, Texas  *(10/01/2019-06/26/2020)*

Co-Chair*  
T. Ryan Greenawalt  
Managing Director  
Ramirez & Co.  
Los Angeles, CA  *(07/01/2020-present)*

Co-Chair*  
Kevin McClatchy  
Chairman of the Board  
The McClatchy Company  
West Palm Beach, FL  *(07/01/2020-present)*

Treasurer  
Raymond F. Schinazi, PhD, DSc  
Frances Winship Walters Professor  
Emory University School of Medicine  
Atlanta, GA  *(deceased 10/26/2019)*

Secretary*  
Arlen H. Andelson  
Senior Partner (retired)  
Andelson & Andelson  
Los Angeles, CA  *(12/19/2019)*

Secretary*  
Jay Ellis  
Jay Ellis Foundation  
Los Angeles, CA  *(12/19/2019)*

TRUSTEES

Danielle Alexandra  
CEO, London Film and Television Group  
Business Ambassador, Film, Television and Global Digital New Media  
Los Angeles, CA

David Bohnett  
Chairman  
David Bohnett Foundation  
Beverly Hills, CA

Donald Dye  
Chairman, Sky Lake Partners  
New York, NY

Aileen Getty  
The Aileen Getty Foundation  
Reno, NV

Glenn Isaacson  
Vice Chairman  
Global Brokerage  
Cushman & Wakefield  
New York, NY

Michael Lorber  
Senior Vice President  
Douglas Elliman Real Estate  
New York, NY

Edward Milstein  
Co-Chairman  
Milstein Brothers Capital Partners  
New York, NY

Jeffrey Schoenfeld  
Partner  
Head of Global Institutional Business Development & Relationship Management  
Brown Brothers Harriman  
New York, NY

Alan Schwartz  
Executive Chairman  
Guggenheim Partners, LLC  
New York, NY

Mario Stevenson, Ph.D.  
Professor of Medicine  
Chief, Division of Infectious Diseases  
Leonard M. Miller School of Medicine  
University of Miami  
Miami, FL

Phil Wilson  
Founder and CEO, Black AIDS Institute (retired)  
Los Angeles, CA

TRUSTEE EMERITUS

Arthur J. Ammann, M.D.  
President, Global Strategies for HIV Prevention  
Clinical Professor of Pediatrics  
University of California, San Francisco  
San Francisco, CA

IN MEMORIAM

Mathilde Krim, Ph.D.  
Founding Chairman

Dame Elizabeth Taylor  
Founding International Chairman

Arlen H. Andelson  
Sheldon W. Andelson, Esq.  
Arnold W. Klein, M.D.  
Mrs. Albert D. Lasker  
Jonathan M. Mann, M.D., M.P.H.  
Maxine Mesinger  
Pauline Phillips  
Natasha Richardson  
Allan Rosenfield, M.D.  
Peter Scott, Esq.  
Wallace Sheft, C.P.A.  
Tom Stoddard  
Joel D. Weisman, D.O.

SPECIAL APPOINTMENT

Global Fundraising Chairman  
Milutin Gatsby

SCIENTIFIC ADVISORY COMMITTEE

*Adjunct Member

Mohamed Abdel-Mohsen, Ph.D.*  
Assistant Professor  
Vaccine & Immunotherapy Center  
The Wistar Institute

Maria Luisa Alcaide, M.D.*  
Associate Professor of Clinical Infectious Diseases  
Miller School of Medicine  
University of Miami

Richard Ambinder, M.D., Ph.D.*  
Director, Division of Hematologic Malignancies  
Professor of Oncology  
School of Medicine  
Johns Hopkins University

Jintanat Ananworanich, M.D., Ph.D.  
Associate Director for Therapeutics Research  
US Military HIV Research Program

Patrick Arbuthnot*  
Professor  
Director, Wits/SAMRC Antiviral Gene Therapy Research Unit  
Faculty of Health Sciences  
University of the Witwatersrand

Robert Arduino, M.D.*  
Professor  
Department of Medicine-Infectious Diseases  
University of Texas Health Science Center at Houston

Judith Auerbach, Ph.D.*  
Professor of Medicine  
School of Medicine  
University of California, San Francisco

Andrew Badley, M.D.*  
Professor  
Mayo Clinic College of Medicine

Ben Berkhour, Ph.D.*  
Professor  
Department of Medical Microbiology  
Academic Medical Center of the University of Amsterdam

Pascal Bessong, Ph.D.*  
Professor of Microbiology and Global Health  
Chair of the HIV/AIDS & Global Health Research Programme  
University of Venda

Daniel Blanco-Melo, Ph.D.*  
Department of Microbiology  
Icahn School of Medicine at Mount Sinai

Eli Bortiz, M.D., Ph.D.*  
Chief, Virus Persistence and Dynamics Section (VPDSS)  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health

Alberto Bosque, Ph.D.*  
Assistant Professor  
Department of Microbiology, Immunology, and Tropical Medicine  
The George Washington University
Deborah Persaud, M.D.*
Professor
School of Medicine
Pediatric Infectious Disease
Bloomberg School of Public Health
Microbiology and Molecular Immunology
Johns Hopkins University

Matija Peterlin, M.D.
Professor of Medicine, Microbiology and Immunology
Department of Medicine
University of California, San Francisco

Christopher Peterson, Ph.D.*
Staff Scientist
Fred Hutchinson Cancer Research Center

Lynn Pulliam, Ph.D.
Professor
Department of Laboratory Medicine and Medicine
University of California, San Francisco
Veterans Affairs Medical Center

Reena Rajsuria, Ph.D.*
Pharmacy Lecturer
University of Malaya

Christina Ramirez, Ph.D.*
Professor of Biostatistics
Fielding School of Public Health
University of California, Los Angeles

Lee Ratner, M.D., Ph.D.
Professor
Department of Medicine
Washington University School of Medicine

Roger Keith Reeves, Ph.D.*
Associate Professor of Medicine
Harvard Medical School
Ragon Institute of MGH, MIT, and Harvard
Director, Harvard CFAR Advanced Laboratory Technologies Core
Center for Virology and Vaccine Research
Beth Israel Deaconess Medical Center

Andrew Rice, Ph.D.
Professor
Department of Molecular Virology and Microbiology
Baylor College of Medicine

Nadia Roan, Ph.D.*
Associate Professor
Department of Urology
University of California, San Francisco

Melissa Robbiani, Ph.D.
Senior Scientist and Director of Biomedical HIV Research
Center for Biomedical Research
Population Council

Mitchell Rosner, M.D.*
Henry B. Multhoff Professor of Medicine
Chair, Department of Medicine
University of Virginia

Ruth M. Ruprecht, M.D., Ph.D.
Scientist, Department of Virology and Immunology
Southwest National Primate Research Center
Director, Texas Biomed AIDS Research Program
Texas Biomedical Research Institute

Timothy Schacker, M.D.*
Vice Dean for Research, Medical School
Director, Program in HIV Medicine
Director, Clinical Translational Research Services,
Clinical and Translational Science Institute (CTSI)
Professor of Medicine, Division of Infectious Diseases and International Medicine
University of Minnesota

Joshua Schiffer, M.D.*
Associate Member
Vaccine and Infectious Disease Division
Associate Member
Clinical Research Division
Fred Hutchinson Cancer Research Center

Frederick A. Schmitt, Ph.D.
Professor
Departments of Neurology, Psychiatry, and Psychology and Behavioral Science
Sanders Brown Center on Aging
University of Kentucky

Gerald Schochetman, Ph.D.
Senior Director
Diagnostics Research
Abbott Laboratories

Sagi Shapira, Ph.D.*
Assistant Professor of Systems Biology
Department of Microbiology & Immunology
Columbia University

Alex Sigal, Ph.D.*
Group Leader, Max Planck Institute for Infection Biology
Africa Health Research Institute (AHRI)

Viviana Simon, M.D., Ph.D.*
Professor
Department of Microbiology
Department of Medicine, Infectious Diseases
Icahn School of Medicine at Mount Sinai

Gail Skowron, M.D.
Professor of Medicine
Boston University School of Medicine

Natalia Soriano-Sarabia, Ph.D.*
Assistant Professor
Department of Microbiology, Immunology and Tropical Medicine
School of Medicine and Health Sciences
The George Washington University

Leonidas Stamatatos, Ph.D.*
Member
Fred Hutchinson Cancer Research Center
Vaccine and Infectious Disease Division
Immunology and Vaccine Development Program

Spyridon Stavrou, Ph.D.*
Assistant Professor
Department of Microbiology and Immunology
Jacobs School of Medicine & Biomedical Sciences
State University of New York at Buffalo

Kathryn Stephenson, M.D.*
Assistant Professor of Medicine
Department of Medicine
Beth Israel Deaconess Medical Center

Mario Stevenson, Ph.D.
Professor of Medicine
Chief, Division of Infectious Diseases
University of Miami Leonard M. Miller School of Medicine

Lydie Trautmann, Eng.D., Ph.D.*
Chief
Cellular Immunology Section
U.S. Military HIV Research Program

Sebastien Viel, PharmD, Ph.D.*
Visiting Associate Professor
Department of Pediatrics
Stanford University

David Vlahov, Ph.D., R.N.
Professor of Nursing,
Epidemiology, and Biostatistics
University of California, San Francisco

David J. Volsky, Ph.D.
Professor of Medicine and Pathology
Icahn School of Medicine at Mount Sinai
Director of Molecular Virology Laboratory
Department of Medicine
Mount Sinai St. Luke’s and Roosevelt Hospitals

Angela Wahl, Ph.D.*
Assistant Professor
Division of Infectious Diseases
UNC School of Medicine

Misaki Wayengera, MBChB., MSc Immunology, Ph.D.*
Department of Pathology
College of Health Sciences
Makerere University

Steven S. Witkin, Ph.D.
Professor of Immunology
Department of Obstetrics and Gynecology
Weill Cornell Medical College

Peter R. Wolfe, M.D.
Associate Clinical Professor
David Geffen School of Medicine
University of California, Los Angeles
Sub-Investigator
Ruane Clinical Research

Kim Woodrow, Ph.D.*
Associate Professor
Department of Bioengineering
University of Washington

Richard T. Wyatt, Ph.D.
Professor of Immunology
IAVI Center for Neutralizing Antibodies
The Scripps Research Institute

Gert van Zyl, Ph.D.*
Associate Professor
Division of Medical Virology
Department of Pathology
Faculty of Medicine & Health Sciences
Stellenbosch University

Lydie Trautmann, Eng.D., Ph.D.*
Chief
Cellular Immunology Section
U.S. Military HIV Research Program

Sebastien Viel, PharmD, Ph.D.*
Visiting Associate Professor
Department of Pediatrics
Stanford University

David Vlahov, Ph.D., R.N.
Professor of Nursing,
Epidemiology, and Biostatistics
University of California, San Francisco

David J. Volsky, Ph.D.
Professor of Medicine and Pathology
Icahn School of Medicine at Mount Sinai
Director of Molecular Virology Laboratory
Department of Medicine
Mount Sinai St. Luke’s and Roosevelt Hospitals

Angela Wahl, Ph.D.*
Assistant Professor
Division of Infectious Diseases
UNC School of Medicine

Misaki Wayengera, MBChB., MSc Immunology, Ph.D.*
Department of Pathology
College of Health Sciences
Makerere University

Steven S. Witkin, Ph.D.
Professor of Immunology
Department of Obstetrics and Gynecology
Weill Cornell Medical College

Peter R. Wolfe, M.D.
Associate Clinical Professor
David Geffen School of Medicine
University of California, Los Angeles
Sub-Investigator
Ruane Clinical Research

Kim Woodrow, Ph.D.*
Associate Professor
Department of Bioengineering
University of Washington

Richard T. Wyatt, Ph.D.
Professor of Immunology
IAVI Center for Neutralizing Antibodies
The Scripps Research Institute

Gert van Zyl, Ph.D.*
Associate Professor
Division of Medical Virology
Department of Pathology
Faculty of Medicine & Health Sciences
Stellenbosch University
Mervyn F. Silverman, M.D., M.P.H. (Chairman)
President
Mervyn F. Silverman Associates
Crockett, CA

Judith D. Auerbach, Ph.D.
Science and Policy Consultant, and Professor
School of Medicine
University of California, San Francisco

David Bloom, Ph.D.
Clarence James Gamble Professor of Economics and Demography
Department of Global Health and Population
Harvard T.H. Chan School of Public Health
Boston, MA

Tim Brown, Ph.D.
Senior Fellow
The East-West Center
Honolulu, HI

Daniel Douek, M.D., Ph.D.
Chief, Human Immunology Section
Vaccine Research Center
National Institute of Allergy and Infectious Diseases
National Institutes of Health

Daria J. Hazuda, Ph.D.
Vice President, Scientific Affairs for Infectious Disease
Merck & Company, Inc.
West Point, PA

Katherine Luzuriaga, M.D.
Professor, Molecular Medicine, Pediatrics and Medicine
University of Massachusetts Medical School
Worcester, MA

Kenneth H. Mayer, M.D.
Infectious Disease Attending and Director of HIV Prevention Research
Beth Israel Deaconess Medical Center

Professor of Medicine
Harvard Medical School

Medical Research Director and Co-Chair
The Fenway Institute/Fenway Health

Jeffrey L. Sturchio, Ph.D.
President and Chief Executive Officer
Rabin Martin, NYC

Visiting Scholar
The Institute for Applied Economics, Global Health and the Study of Business Enterprise
Johns Hopkins University

Member
The Council on Foreign Relations

Annette Sohn, M.D.
Vice President, Public Information

MANAGEMENT GROUP

Kevin Robert Frost
Chief Executive Officer

Anthony Ancona
Vice President and Director, Human Resources

Susan J. Blumenthal, M.D., M.P.A.
Senior Policy and Medical Advisor

Kyle Clifford
Vice President, Development
(June 2020—present)

Bradley Jensen
Chief Financial Officer

Rowena Johnston, Ph.D.
Vice President and Director, Research

Jeffrey Laurence, M.D.
Senior Scientific Consultant for Programs

Gregorio Millett, M.P.H.
Vice President and Director, Public Policy

Eric Muscatell
Vice President, Development
(through May 2020)

AnnMari Shannahan
Vice President, Public Information

Los Angeles, CA
amfAR, The Foundation for AIDS Research

NEW YORK
120 Wall Street, 13th Floor
New York, NY 10005-3908
(212) 806-1600 (tel)
(212) 806-1601 (fax)

WASHINGTON, D.C.
1100 Vermont Avenue, NW
Suite 600
Washington, DC 20005
(202) 331-8600 (tel)
(202) 331-8606 (fax)

BANGKOK, THAILAND
TREAT Asia
Exchange Tower
388 Sukhumvit Road, Suite 2104
Klongtoey, Bangkok 10110
Thailand
+66 (0)2 663 7561 (tel)
+66 (0)2 663 7562 (fax)

www.amfar.org